Shattuck Labs (STTK)

Executive Summary

Shattuck Labs is a clinical-stage biotechnology company pioneering first-in-class DR3-blocking monoclonal antibodies for immune-mediated disorders, with a primary focus on inflammatory bowel disease (IBD). The company's lead candidate, SL-325, is an Fc-silenced antibody targeting the TL1A/DR3 signaling axis, designed to achieve superior efficacy and a favorable immunogenicity profile compared to existing TL1A-blocking therapies. Currently, SL-325 is in a Phase 1 healthy volunteer trial (NCT07158437) expected to complete in July 2026, with data readout anticipated thereafter. Previous programs, including SL-172154 in oncology, have been terminated, reflecting a strategic pivot toward IBD. With a public listing and a market valuation of approximately $492 million, Shattuck Labs represents a high-risk, high-reward opportunity in the competitive IBD landscape. Success in Phase 1 and subsequent Phase 2 trials could position the company as a key player in the TL1A space, but early-stage clinical risk and lack of approved products temper the outlook.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 Healthy Volunteer Study Completion and Safety Data75% success
• Q1 2027Initiation of Phase 2 Trial in IBD50% success
• TBDPotential Partnership or Licensing Deal30% success